<DOC>
	<DOC>NCT02008942</DOC>
	<brief_summary>This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric coated aspirin, when administered to patients with diabetes</brief_summary>
	<brief_title>Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>NonInsulinDependent Diabetes Mellitus Adults 21 to 79 years, inclusive Body mass index between 30 and 40 kg/m2, inclusive Currently prescribed aspirin or anticoagulants Contraindications to aspirin Significant disease history or active disease other than NonInsulinDependent Diabetes Mellitus Patient requires insulin</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>